Can These Stocks Rebound From Their Recent Losses? Arrowhead Research Corp(NASDAQ:ARWR), Banro Corporation (USA)(NYSEMKT:BAA), and Celldex Therapeutics, Inc.(NASDAQ:CLDX)

Posted by admin August 22, 2014 0 Comment 737 views

New York, NY – 08/22/2014 –  HotStockGains provides investors  and traders with valuable trading strategies via text message and email. To join our free text message alerts service just text the word BREAKOUT to 555888 from your cell phone. Just text STOP to unsubscribe if you ever need to.

Arrowhead Research Corp(NASDAQ:ARWR) lost ninety-three cents to finish the day at a closing price of $12.72. The biopharmaceutical company’s trading volume spiked to a figure of 4,029,047, a figure which is 1,433,977 higher than its three month average of 2,595,070. Arrowhead Research Corp(NASDAQ:ARWR) reported its quarterly financial results on the morning of Aug. 18th. Along with the financial figures, which include no meaningful revenue, Arrowhead also announced that its Phase IIb study of ARC-520 would commence during the fourth quarter of the 2014 year.

Is Arrowhead’s ARC-520 Study Worth Your Investment? Take A Look At Our Free ARWR Analysis.

Banro Corporation (USA)(NYSEMKT:BAA) saw its value decline by 3.45% yesterday as the stock fell $0.009, moving to a new closing price of $0.26. The stock has traded within a range of $0.18 to $1.13 over the past 52 weeks. On Aug. 14th, the Ontario-based company reported its second quarter financial results, which included revenue and net loss figures of $26.5 and $3.0 million, respectively. Since the announcement, Banro’s value has risen by seven cents from $0.18.

Can Banro Maintain Its Upward Momentum Despite Yesterday’s Loss? Receive A Free BAA Analysis.

Celldex Therapeutics, Inc.(NASDAQ:CLDX) lost eighty cents to finish the day at a closing price of $14.31. The 5.29% decrease in value did not come in response to a recent news report or press release. Celldex Therapeutics, Inc.(NASDAQ:CLDX) has closed within a range of $12.05 to $17.57 over the past three months. The New Jersey-based biopharmaceutical company is currently developing treatments for front-line and recurrent glioblastoma, with studies in both the second and third phases.

Why Is Celldex Therapeutics Falling? Click Here For A Free CLDX Analysis.

About HotStockGains

I have a confession to make – I am not always right. Sometimes, unfortunately, I will send alerts that experience losses.

I have alerted companies that rallied 100% or even 6,000% (not even joking) in under a week. Likewise, I have alerted companies that tanked 10, 20, sometimes even as much as 30 or 40%. However overall it is about the net result that delivers profits into your portfolio.

Sign up for my free newsletter to receive market insight, tips, and trading strategies on NYSE, NASDAQ, OTCBB and PINK stocks. If you are not satisfied, simply click unsubscribe.

Disclosure:  HotStockGains is not a registered investment adviser and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Always seek help from a professional financial advisor (I am not one). Please visit for complete risks and disclosures.

Write Your Comment